Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 May 11;96(10):5340-2.
doi: 10.1073/pnas.96.10.5340.

Inducing autoimmune disease to treat cancer

D M Pardoll

Inducing autoimmune disease to treat cancer

D M Pardoll. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Depiction of tumor antigen immunity as a potential energy diagram. Under normal circumstances, the level of endogenous immunity against a tumor antigen is below a critical threshold necessary for clinical antitumor immunity. Generation of an antitumor response would require the elevation of immunity against a particular antigen above a critical threshold. The stringency of tolerance against a particular antigen is represented by the “distance” of the endogenous immunity level below the reactivity threshold level (A). If one chooses an antigen against which immune tolerance is stringently maintained, even a strong adjuvant will not raise the level of immunity above the critical threshold and the vaccine will fail (B). If one chooses an antigen against which immune tolerance is less stringently maintained but uses a weak adjuvant, the vaccine also will fail (C). However, if one uses a strong adjuvant to present an antigen against which endogenous tolerance is relatively nonstringent, then it will be easier to elevate the level of immunity against that antigen above the critical threshold and the vaccine will succeed (D).
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Overwijk W W, Lee D S, Surman D R, Irvine K R, Touloukian C E, Chan C-C, Carroll M W, Moss B, Rosenberg S A, Restifo N P. Proc Natl Acad Sci USA. 1999;96:2982–2987. - PMC - PubMed
    1. Prehn R T. J Natl Cancer Inst. 1957;18:769–778. - PubMed
    1. Schreiber H, Ward P L, Rowley D A, Strauss H J. Annu Rev Immunol. 1988;6:465–483. - PubMed
    1. Kastan M B, Zhan Q E L, Deiry W S, Carrier F, Jacks T, Walsh W V, Plunkett B S, Vogelstein B, Fornace A J J. Cell. 1992;71:587–597. - PubMed
    1. Old L J. Cancer Res. 1981;41:361–375. - PubMed

LinkOut - more resources